Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
Conditions
Interventions
Intravitreal aflibercept injection [IAI]
Sham
Locations
89
United States
Regeneron Study Site
Phoenix, Arizona, United States
Regeneron Study Site
Tucson, Arizona, United States
Regeneron Study Site
Arcadia, California, United States
Regeneron Study Site
Beverly Hills, California, United States
Regeneron Study Site
Encino, California, United States
Regeneron Study Site
Fullerton, California, United States
Start Date
March 29, 2016
Primary Completion Date
August 6, 2018
Completion Date
July 16, 2019
Last Updated
July 30, 2020
NCT05383209
NCT03197870
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions